

## Financial Results Briefing for Q3/2020

August 3, 2020







This report contains forward-looking statements on business performance based on the judgments, assumptions, and beliefs of management using the information available at the time. Actual results may differ materially due to changes in domestic or overseas economic conditions or changes in internal or external business environments or aspects of uncertainty contained in the forecasts, latent risks or various other factors. In addition, risk and uncertainty factors include unpredictable elements that could arise from future events.



#### Measures to prevent the spread of COVID-19











#### Measures to prevent the spread of COVID-19

#### For employees



#### Rate for remote work

Over 95% achieved since March

99% achieved for the March to June period. Rate of office work has remained at around 5% daily even after July.

## Institutionalizing remote work

Subsidizing employees to raise children and enhancing mental healthcare system.

#### Measures to prevent the spread of COVID-19

#### For trade partners

Leveraging sales capabilities (face-to-face/online) x IT, adopt optimal marketing strategies in quick response to environmental changes



Sales method:

Sales target:

Face-to-face sales

Cloud drug record service

**Online sales** 

Online medical examination
Online medication advice

Online sales main

Online medical examination Online medication advice Cloud drug records system

#### Contents

#### P.01 Financial Results Overview for Q3

- 02 Financial highlight
- 03 Consolidated P/L
- 04 Consolidated SG&A
- 05 Progress of full-year earnings forecast
- 06 Performance by B/U

#### P.30 Appendix

## P.13 Measures to be adopted

- 14 Basic policy in FY2020
- 15 Online medical examination and Online medication advice
- 22 Cloud drug record service
- 27 Healthcare Business
- 28 Content Business
- 29 Consolidated earnings forecast
- 31 Consolidated B/S 34 Earning by B/U
  32 Consolidated P/L 36 List of main healthcare services
  33 Consolidated SG&A 37 Overview of healthcare services



#### **Financial Results Overview for Q3 FY2020**

#### Financial highlight

- 1 Q3 Results
  - Net sales ¥19,452 million (Down ¥975million, Down ¥4.8%, YoY)
  - Operating income ¥2,017 million (Down ¥247million, Down ¥10.9%, YoY)
- Reasonable results achieved in terms of the full-year earnings forecast

Progress rate
Net sales 74.8% Operating income 80.7%

- **Q3 Achievements and initiatives** 
  - Extensive introduction for online medical examination and Online medication advice
  - Extensive introduction for cloud drug record service
  - Brisk original comics content business



#### Consolidated P/L

## **Decreased sales and profit COVID-19 coronavirus impact limited**

				(Unit : Mil yen)	
	FY2020 Q3	FY2019 Q3	Yo	Υ	
	Cumulative total	Cumulative total	Amount	Percentage	
Net sales	19,452	20,427	(975)	(4.8%)	Separation between telecommunication
Cost of sales (ratio)	<b>5,315</b> 27.3%	5,168 25.3%	+147	+2.9%	and smartphones (regulation implication)
Gross profit (ratio)	<b>14,136</b> 72.7%	15,259 74.7%	(1,123)	(7.4%)	implication)
SG&A	12,119	12,994	(875)	(6.7%)	Reduction of advertising
(ratio) Operating income	62.3% <b>2,017</b>	63.6% 2,265	(247)		expenses
(ratio) Ordinary income	10.4% <b>1,961</b>	11.1% 2,951	(989)	(33.5%)	
(ratio)	, 10.1%	, 14.4%	,	,	
Profit attributable to owners of parent	1,780	2,146	(365)	(17.0%)	
(ratio)	9.2%	10.5%			



#### **Consolidated SG&A:**

#### Significant reduction of Advertising expenses

(Unit: Mil ven)

				(Offic: Mill yell)	
	FY2020 Q3	FY2019 Q3	Yo	Υ	
	Cumulative total	Cumulative total	Amount	Percentage	
SG&A	12,119	12,994	(875)	(6.7%)	Separation between
Advertising expenses	853	1,990	(1,136)	(57.1%)	telecommunication and smartphones (regulation
Personnel expenses	4,664	4,651	+12	+0.3%	implication)
Commission fee	2,527	2,594	(66)	(2.6%)	
Subcontract expenses	1,020	739	+281	+38.1%	
Depreciation	1,182	1,003	+179	+17.9%	
Other	1,870	2,015	(145)	(7.2%)	4



#### **Progress of full-year earnings forecast**

#### Reasonable results achieved

(Unit: Mil yen)

	FY2020 Q3	FY2020	Progress
	Cumulative total	Forecast	rate
Net sales	19,452	26,000	74.8%
Operating income	2,017	2,500	80.7%
Ordinary income	1,961	2,400	81.7%
Profit attributable to owners of parent	1,780	1,700	104.7%

#### Performance by B/U

#### **Content Business**

BtoC/BtoB

Content distribution service








#### Other Business


BtoB/BtoBtoC Fintech service AI service






#### Performance by B/U





#### Content business: Net sales and operating income



## Net sales and operating income levelled off


Net sales

Brisk original comics content business
The effect of accepting the transfer of "musico"

Operating income

Significant reduction of advertising expenses
The effect of accepting the transfer of "musico"

#### Content business: The number of paying subscribers




#### **Declining trend**

Separation between telecommunication and smartphones (regulation implication)

Q1: The effect of accepting the transfer of "musico"

<sup>\*</sup> The number of paying subscribers are including healthcare business 'Luna-luna and 'Caradamedica' whose business model are monthly paid business above.

#### **Content business: ARPU**




#### **ARPU** levelled off

Separation between telecommunication and smartphones (regulation implication)



#### Healthcare business: Net sales and operating income




# Net sales levelled off, but investment was maintained

- Net sales
   Sales expanded for the initial introduction of cloud drug record service.
- Operating loss
   Higher advertising expenses for online medical examination and medication advice.



#### Other business(AI business): Net sales and operating income

System development for financial institutions and other solution business



- Net sales
   Seasonal factors in AI
   Business
- Operating loss
   Seasonal factors in AI Business



- 紫永会計工ムティーアイ

#### Measures to be adopted



#### **Basic policy in FY2020**


- 1. Expand sales for healthcare services
- 2. Maintenance of the total number of paying subscribers
- 3. Improvement in ARPU

Linking medical institutions and patients

## Online medical examination and Online medication advice



## Online medical examination and online medication advice1: Achievements and initiatives



# Surging demand with rapid growth in the number of service contracts Q3 results

- Rapid growth in demand in the wake of COVID-19
- Using listing ads

#### Approaches in Q4 and beyond

- Paid services to start in the next term
- Collaboration with Medipal Holdings Corporation in Marketing




#### Online medical examination and online medication advice 2:

### What is 'online medical examination'?

Internet-based medical services provided to non-hospitalized patients that are performed by healthcare professionals.

### What is 'online medication advice'?

Internet-based medication advice for prescribed drugs usually performed by pharmacists. Patients receive drugs with internal prescription at home. They receive external prescriptions forwarded to their smartphones. This service replaces the process of drug purchases by patients at pharmacies with medication instructions.





## Online medical examination and online medication advice3: Operating environment

Previously

Temporary measure

After COVID-19 4/10~

First visit

Online medical examination not appropriate Face-to-face medical examination required

Online medical examination allowed for new patients

Target disease

High blood pressure, diabetes, certain chronic diseases only

No limitation with doctor's discretion

Deregulation underway for online medical examination and online medication advice



## Online medical examination and online medication advice4: Service introduction

#### CARADA medica

A full spec online system that handles every step from reservation, to video call, settlement and drug delivery.

#### Full spec

#### Reservation

By allowing patients to

make reservations for

wasted time can be

avoided in medical

practice.

date and hour of medical

examination in advance,

#### T

#### Video call

An online medical consultation and examination are conducted through a video call, easing the burden on healthcare professionals because they can speak to the patient while checking his/her facial expressions.

#### Settlement



Settlement is made automatically after online medical consultation and examination, using the credit card registered by the patient in advance.

### Delivery of drugs and prescriptions




A delivery firm collects the drugs and prescriptions from medical institutions and delivers them to patients.

Copyrights (c) 2020 MTI Ltd. All Right Reserved

## Online medical examination and online medication advice 5: Market

Rapid growth in demand in the wake of COVID-19



Number of clinics across the nation

100,000 clinics

Number of pharmacies across the nation  $60,000_{\text{pharmacies}}$ 

Estimated to be Interested in online services 20%

Future revenue scheme (Currently provided for free)

**Spot type** 

+

Initial cost for introduction

Stock type

Monthly charge for system usage



## Online medical examination and online medication advice 6: Topics



"LunaLuna online medical examination" Introduced by St. Marianna University School of Medicine for infertility treatment

Online consultation possible for infertility treatment

#### Linking medical institutions and patients




#### What is 'medication history'?

Patient's drug prescription records

Pharmacists at pharmacies dispense drugs based on doctor's prescriptions. After the drugs are administered, they monitor the effects and possible adverse effects through direct interaction with patients to prepare a drug administration history for each patient.

#### Cloud drug record service 1: Achievements and initiatives



#### Extensive introduction, Resumed sales activities

#### Q3 results

- A shift is underway toward online medication advice in terms of marketing priorities
- More introductions to pharmacies as existing customers

#### Approaches in Q4 and beyond

- IT subsidy program helps initial installation cost
- Collaboration with Medipal Holdings Corporation in Marketing



#### Cloud drug record service 2: Operating environment

Challenges in the healthcare industry

(primarily those closely related to pharmacies) )

National health insurance budget: 42.6 trillion yen

Pharmacy errors (incorrect medication or prescription)

→ Stronger regulations underway for 60,000 pharmacies across the nation

#### Revenue of dispensing pharmacies is declining

On a declining trend reflecting government revisions in drug prices and drug compounding fees



①Drug fee



<sup>2</sup>Drug compounding fee

+




#### Remuneration (revenue) of dispensing pharmacies

#### Challenges for pharmacies

#### Increasing workload for dispensing pharmacies and pharmacists

Given the large number of input items for medication histories, the burden for pharmacists after business hours is heavy. Certain drug medications may be considered fraudulent unless they are provided in accordance with administrative guidelines requiring accurate statement of medication history. It will be necessary to establish a system capable of facilitating efficient operations for pharmacists who will face further increases in their workload.



A system facilitating efficient operations for pharmacists in preparing medication histories

Solamichi solves the problem!

Management

Priority is to

 $r_{e_{Ve_{n_{U_{e}}}}}$ 

<sup>\*</sup>Evaluation of drug management service, medication advice, drug information and home medication services provided by pharmacists.

#### Cloud drug record service 3: Service introduction

A system facilitating efficient operations for pharmacists in preparing medication histories

#### Solamichi



With medication instructions

Providing comprehensive support for new drug medication instruction services added to the medical payment system!

A user-friendly operation screen


Well received by practicing pharmacists!

Accessible even outside pharmacies

Effective with familiar pharmacies!

#### Cloud drug record service4: Market

Market development with cloud technologies



revenue scheme

Spot type

Initial cost for introduction

Stock type

Monthly charge for system usage



#### **Healthcare business:**

#### Promote collaboration with major prescription pharmaceutical wholesaler


## Commodity (Service)



#### Sales system



#### **Content business: Achievements and initiatives**



## Brisk original comics content business

#### Q3 results

Stay-at-home demand helped

#### Approaches in Q4 and beyond

Growth in the number of popular original comic content



#### **Consolidated earnings forecast**

常気会能工ムティーアイ

(Unit : Mil yen)

		FY2020		FY:	2019 (Actua	al)	Yo	ρΥ
	Full year (Forecast)	H1 (Actual)	H2 (Forecast)	Full year	H1	H2	Amount Full year	Ratio Full year
Net sales	26,000	12,946	13,053	27,112	13,932	13,179	(1,112)	(4.1%)
Cost of sales	7,200	3,531	3,668	7,517	3,515	3,641	+42	+0.6%
Gross profit	18,800	9,414	9,385	19,955	10,416	9,538	(1,155)	(5.8%)
SG&A	16,300	7,968	8,331	16,996	8,781	8,214	(696)	(4.1%)
Operating income	2,500	1,446	1,053	2,959	1,635	1,323	(459)	(15.5%)
(Ratio)	9.6%	11.2%	8.1%	10.9%	11.7%	10.0%		
Ordinary income	2,400	1,310	1,089	3,134	1,577	1,556	(734)	(23.4%)
(Ratio)	9.2%	10.1%	8.3%	11.6%	11.3%	11.8%		
Profit attributable to owners of parent	1,700	1,246	453	1,508	860	647	(191)	(12.7%)
(Ratio)	6.5%	9.6%	3.5%	5.6%	6.2%	4.9%		

| 漢語(会計||正仏ティーアイ

## **Appendix**

#### MTI Ltd.

#### **Consolidated B/S**

(Unit : Mil yen)

	FY2020-3Q	FY2019	Change		FY2020-3Q	FY2019	Change
Current assets	19,217	18,469	+748	Current liabilities	4,421	4,315	+106
Cash and deposit	12,724	12,421	+303	Accounts payable-trade  Current portion of long-term borrowings	1,178 451	1,308 14	(129) +437
Notes and accounts receivable-trade	4,909	4,667	+242	Account payable-other	1,320	1,150	+169
Other	1,632	1,427	+204	Income taxes payable	359	730	(371)
Allowance for doubtful accounts	(48)	(47)	(1)	Allowance for coin usage	124	143	(19)
				Other	986	968	+18
Non-current assets	12,473	9,010	+3,463	Non-current liabilities	4,426	1,370	+3,056
Property, plant and equipment	213	258	(44)	Long-term borrowings	3,024	52	+2,972
Intangible fixed assets	5,392	2,062	+3,330	Retirement benefit liability	1,395	1,306	+88
(Include) software	2,124	1,870	+253	Other	7	11	(3)
goodwill	1,331	153	+1,178	Total liabilities	8,848	5,685	+3,163
Customer-related assets	1,860	-	+1,860	Shareholders' equity	20,388	19,598	+790
Investments and other assets	6,866	6,689	+176	Capital stock	5,135	5,135	-
(Include) investment securities	4,856	4,977	(120)	Capital surplus	6,553	6,706	(153)
Deferred tax assets	1,458	1,133	+324	Retained earning	11,978	10,989	+989
				Treasury shares	(3,278)	(3,233)	(45)
				Accumulated other comprehensive income	16	268	(252)
				Subscription rights to shares	375	343	+32
				Non-controlling interests	2,062	1,584	+478
				Total net assets	22,843	21,794	+1,048
Total assets	31,691	27,479	+4,212	Total liabilities and net assets	31,691	27,479	+4,212



#### Trends in consolidated P/L

- 満試会社エムティーアイ

(Unit: Mil yen)

		FY2	018			FY2	.019		FY2	020	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q
Net sales	7,517	7,645	7,036	6,876	6,862	7,070	6,495	6,684	6,104	6,842	6,505
Cost of sales	1,590	1,734	1,499	1,580	1,632	1,883	1,652	1,989	1,627	1,904	1,783
Gross profit	5,926	5,910	5,537	5,295	5,229	5,186	4,843	4,695	4,477	4,937	4,722
(Ratio)	78.8%	77.3%	78.7%	77.0%	76.2%	73.4%	74.6%	70.2%	73.3%	72.2%	72.6%
SG&A	5,265	5,200	4,444	4,542	4,400	4,380	4,213	4,001	3,891	4,076	4,151
Operating income	661	710	1,092	753	829	806	629	694	586	860	570
(ratio)	8.8%	9.3%	15.5%	11.0%	12.1%	11.4%	9.7%	10.4%	9.6%	12.6%	8.8%
Ordinary income	619	706	1,085	705	868	709	1,373	183	404	905	651
(Ratio)	8.2%	9.2%	15.4%	10.3%	12.7%	10.0%	21.1%	2.7%	6.6%	13.2%	10.0%
Profit attributable to owners of parent	801	352	740	(266)	543	317	1,285	(638)	231	1,014	534
(Ratio)	10.7%	4.6%	10.5%	-	7.9%	4.5%	19.8%	_	3.8%	14.8%	8.2%



#### **Trends in consolidated SG&A**

常式会社エムティーアイ

(Unit : Mil yen)

		FY2	018			FY2	.019		FY2	020	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q
SG&A	5,265	5,200	4,444	4,542	4,400	4,380	4,213	4,001	3,891	4,076	4,151
Advertising expense	1,369	1,487	721	822	722	763	504	414	248	241	362
Personnel expenses	1,534	1,456	1,500	1,324	1,550	1,516	1,584	1,496	1,550	1,561	1,551
Commission fee	886	938	884	913	880	844	869	805	829	844	853
Subcontract expenses	282	240	240	361	216	248	274	328	278	345	396
Depreciation	430	422	412	373	343	332	326	323	307	450	425
Other	761	654	685	746	687	673	654	632	675	632	562



#### Trends in performance by business units (Net sales)

(Unit: Mil yen)

		FY201	19		FY202	20	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q
Net sales	6,862	7,070	6,495	6,684	6,104	6,842	6,505
Content business	5,508	5,348	5,269	4,975	4,878	5,136	5,179
Healthcare business	886	933	851	905	809	911	873
Other business	467	788	374	803	416	794	453
Cost department	-	-	-	-	-	-	-
Elimination of consolidation	-	-	-	-	-	-	-





#### Trends in performance by business units (Operating income)

(Unit: Mil yen)

		FY201	.9		FY202	.0	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q
Operating income	829	806	629	694	586	860	570
Content business	1,765	1,537	1,738	1,578	1,672	1,785	1,798
Healthcare business	(412)	(346)	(394)	(363)	(453)	(440)	(495)
Other business	(127)	(44)	(187)	(119)	(164)	(22)	(242)
Cost department	(411)	(326)	(503)	(381)	(459)	(430)	(442)
Elimination of consolidation	15	(13)	(23)	(20)	(9)	(32)	(46)




#### The list of main healthcare services

Figures are the actual as of end of July 2020.

		rigures are the actual as of end of July 2020.
Name of service	Service of function	Business model
母子モ	Maternal and Child Health Handbook service app. Vaccine scheduling function, parenting curve and information provided by local governments.	The app is provided at no additional charge for those of childbearing age including mothers.  Collects monthly usage fees from contracted local governments nationwide.  The service has been adopted by 285 of 1,741 local governments nationwide.
Luna & Luna  JL + JL +  Mamonio modical site	Healthcare info service for women. Forecasting menstrual day & ovulation day.	Free app (Over 15 million DL cumulative) Three hundred yen fee or higher for fertility mode and other modes
'Luna luna medico'	LunaLuna linkage function for gynecologists. Daily health information for female patients is shown on hospital computers. The service is for fertility treatment.	The service is currently provided at no additional charge. The service has been adopted by 780 gynecologists. (Patients are LunaLuna users [free/additional charge])
LunaLuna online medical examination	Complete online service provided in a single system, from making reservations for gynecological examinations to delivery of drugs from pharmacies	As a measure to prevent the spread of COVID-19, The service will be provided free of charge until the end of September 2020.
CARADA 健康相談	Q&A service for doctors and people engaged in medical services. Helps eliminate daily health concerns.	¥400/month
CARADA オンライン診療 Online medical examination Online medication advice	the system offers full features that are necessary for online medical examination, from reservations to delivery of drugs and prescriptions .	Contracts with 724 clinics and pharmacies. As a measure to prevent the spread of COVID-19, The service will be provided free of charge until the end of September 2020.
CARADA	Service for medical examination institutions. Results of health checkups, including previous records, are sent to relevant smartphones as a graphic. The service, which enhances users' convenience, contributes to increasing the rate of checkups at health examination institutions.	Collects monthly usage fees from health examination institutions.
Solamichi	Cloud drug administration record service for pharmacies The drug administration record navigation function is highly rated. Links with the CARADA medical history notebook app.	Initial cost for introduction + monthly usage fee 285 orders have been received. Full-scale deliveries started in December 2019.

#### Healthcare business: Overview of Healthcare services



<sup>\*</sup>Some images are under development and may differ from the actual ones.

<sup>\*</sup>The services provided by the Group include some services that provide support for medical sites, but do not perform medical activities.



⟨Contact us⟩

Investor Relations Office TEL: +81-3-5333-6323 FAX: +81-3-3320-0189

e-mail: ir@mti.co.jp https://www.mti.co.jp/eng/

This report contains forward-looking statements on business performance based on the judgments, assumptions, and beliefs of management using the information available at the time. Actual results may differ materially due to changes in domestic or overseas economic conditions or changes in internal or external business environments or aspects of uncertainty contained in the forecasts, latent risks or various other factors. In addition, risk and uncertainty factors include unpredictable elements that could arise from future events.